FDA 1987 appropriations
Executive Summary
House provision prohibiting FDA from using funds to implement user fees was retained in funding bill that passed the Senate Appropriations Committee on Sept. 11. However, the committee added that the agency may keep user fee revenues if such charges are "explicitly authorized" by legislation from Sen. Hatch's (R-Utah) or Rep. Waxman's (D-Calif.) committees. The Senate funding measure provides $438.3 mil. to FDA for 1987 -- $34.7 mil. over the agency's current budget and $1.3 mil. over the House appropriation.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.